Igm compositions and methods of mucosal delivery of these compositions
AssigneeUniversity of Louisiana at Lafayette
InventorsRuth Ruprecht, Siqi Gong
Life of this patent
Estimating the term…
Abstract
Described herein are methods of inducing an immune response directed towards preventing or reducing the risk of a human immunodeficiency virus (HIV) infection in a mammalian subject. The subject is administered an effective amount of a composition containing IgM antibodies directed to an epitope of an envelope protein of the HIV virus. Also disclosed here are vaccine compositions comprising IgM antibodies directed to one or more epitopes of one or more human immunodeficiency virus envelope proteins. Also disclosed are recombinant immunoglobulin M compositions containing a Fcγ fragment of an immunoglobulin G.
Claims21
A method of inducing an immune response directed towards preventing or reducing the risk of a human immunodeficiency virus (HIV) infection in a mammalian subject, comprising
- administering to the mammalian subject an effective amount of a composition containing immunoglobulin M (IgM) antibodies directed to an epitope of a human immunodeficiency virus envelope protein.
A recombinant immunoglobulin M composition, comprising:
- a Fcγ fragment of an immunoglobulin G connected to a carboxy terminus of a joining chain of an immunoglobulin M.
A recombinant immunoglobulin M composition, comprising:
- a Fcγ fragment of an immunoglobulin G connected to a carboxy terminus of a constant region of a light chain of immunoglobulin M.
A recombinant immunoglobulin M composition, comprising:
- a plurality of monomers of a bispecific antibody containing:
- a first constant region linked to a first variable region, wherein the first variable region includes a variable region of a first heavy chain and a variable region of a first light chain capable of specifically binding to a first epitope of a pathogen;
- and
- a second constant region linked to a second variable region, wherein the second variable region includes a variable region of a second heavy chain and a variable region of a second light chain capable of specifically binding to a second epitope of the pathogen.
Dependencies are inferred from the claim text.